|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 2 (January 15), 2000:
pp. 558-563
Human antibodies with specificity for the C2 domain of factor VIII
are derived from VH1 germline genes
Edward N. van den Brink,
Ellen A. M. Turenhout,
Julian Davies,
Niels Bovenschen,
Karin Fijnvandraat,
Willem H. Ouwehand,
Marjolein Peters, and
Jan Voorberg
From the Department of Blood Coagulation, CLB,
Amsterdam; the Laboratory for Experimental and Clinical Immunology,
Academic Medical Centre, University of Amsterdam, Amsterdam; Emma
Children's Hospital Academic Medical Centre, Amsterdam, The
Netherlands; the Department of Hematology, University of Cambridge; the
National Blood Service, Cambridge; and the National Institute for
Biological Standards and Control, Potters Bar, United Kingdom.
A serious complication in hemophilia care is the development of
factor VIII (FVIII) neutralizing antibodies (inhibitors). The authors
used V gene phage display technology to define human anti-FVIII
antibodies at the molecular level. The IgG4-specific, variable,
heavy-chain gene repertoire of a patient with acquired hemophilia was
combined with a nonimmune, variable, light-chain gene repertoire for
display as single-chain variable domain antibody fragments (scFv) on
filamentous phage. ScFv were selected by 4 rounds of panning on
immobilized FVIII light chain. Sequence analysis revealed that isolated
scFv were characterized by VH domains encoded by germline
genes DP-10, DP-14, and DP-88, all belonging to the VH1
gene family. All clones displayed extensive hypermutation and were
characterized by unusually long CDR3 sequences of 20 to 23 amino acids.
Immunoprecipitation revealed that all scFv examined bound to the C2
domain of FVIII. Furthermore, isolated scFv competed with an inhibitory
murine monoclonal antibody for binding to the C2 domain. Even though
scFv bound FVIII with high affinity, they did not inhibit FVIII
activity. Interestingly, the addition of scFv diminished the inhibitory
potential of patient-derived antibodies with C2 domain specificity.
These results suggest that the epitope of a significant portion of
anti-C2 domain antibodies overlaps with that of the scFv isolated in
this study.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Lacroix-Desmazes, A.-M. Navarrete, S. Andre, J. Bayry, S. V. Kaveri, and S. Dasgupta
Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A
Blood,
July 15, 2008;
112(2):
240 - 249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E.H. Afar, V. Bhaskar, E. Ibsen, D. Breinberg, S. M. Henshall, J. G. Kench, M. Drobnjak, R. Powers, M. Wong, F. Evangelista, et al.
Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer
Mol. Cancer Ther.,
August 1, 2004;
3(8):
921 - 932.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Bovenschen, R. C. Boertjes, G. van Stempvoort, J. Voorberg, P. J. Lenting, A. B. Meijer, and K. Mertens
Low Density Lipoprotein Receptor-related Protein and Factor IXa Share Structural Requirements for Binding to the A3 Domain of Coagulation Factor VIII
J. Biol. Chem.,
March 7, 2003;
278(11):
9370 - 9377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Jacquemin, V. Vantomme, C. Buhot, R. Lavend'homme, W. Burny, N. Demotte, P. Chaux, K. Peerlinck, J. Vermylen, B. Maillere, et al.
CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A
Blood,
February 15, 2003;
101(4):
1351 - 1358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. N. van den Brink, W. S. Bril, E. A. M. Turenhout, M. Zuurveld, N. Bovenschen, M. Peters, T. T. Yee, K. Mertens, D. A. Lewis, T. L. Ortel, et al.
Two classes of germline genes both derived from the VH1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII
Blood,
April 15, 2002;
99(8):
2828 - 2834.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-J. Jacobin, J. Laroche-Traineau, M. Little, A. Keller, K. Peter, M. Welschof, A. Nurden, and G. Clofent-Sanchez
Human IgG Monoclonal Anti-{alpha}IIb{beta}3-Binding Fragments Derived from Immunized Donors Using Phage Display
J. Immunol.,
February 15, 2002;
168(4):
2035 - 2045.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Li, C. Yang, Y. Xia, A. Bertino, J. Glaspy, M. Roberts, and D. J. Kuter
Thrombocytopenia caused by the development of antibodies to thrombopoietin
Blood,
December 1, 2001;
98(12):
3241 - 3248.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. N. van den Brink, E. A. M. Turenhout, N. Bovenschen, B. G. A. D. H. Heijnen, K. Mertens, M. Peters, and J. Voorberg
Multiple VH genes are used to assemble human antibodies directed toward the A3-C1 domains of factor VIII
Blood,
February 15, 2001;
97(4):
966 - 972.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Jirholt, L. Strandberg, B. Jansson, E. Krambovitis, E. Soderlind, C. A.K. Borrebaeck, R. Carlsson, L. Danielsson, and M. Ohlin
A central core structure in an antibody variable domain determines antigen specificity
Protein Eng. Des. Sel.,
January 1, 2001;
14(1):
67 - 74.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. N. van den Brink, E. A. M. Turenhout, C. M. C. Bank, K. Fijnvandraat, M. Peters, and J. Voorberg
Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain
Blood,
July 15, 2000;
96(2):
540 - 545.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
